2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Purple Innovation reported second-quarter 2026 net revenue of $98.3 million, down 6.5% from a year earlier, driven by lower wholesale revenue, while its GAAP net loss narrowed to $3.2 million. The company lowered its 2026 revenue guidance to $420 million to $440 million, so shareholders face weaker top-line expectations even as profitability measures improved.
Q2 2026 net revenue was $98.3 million, down 6.5% from $105.1 million; wholesale revenue fell 19.1% to $37.4 million while showroom revenue rose 16.6%
GAAP net loss was $3.2 million, a $14.1 million improvement; adjusted EBITDA was $2.1 million versus a $2.4 million loss a year earlier
2026 revenue guidance lowered to $420 million to $440 million; adjusted EBITDA guidance is $20 million to $25 million
Company regained compliance with the Nasdaq minimum bid price requirement after the quarter ended
Alico reported third-quarter results for the period ended June 30, 2026, with revenue of $9.0 million, up 7.7% from a year earlier, and net income attributable to common stockholders of $2.1 million, or $0.29 per diluted share, compared with a loss of $18.3 million a year earlier. The company raised its fiscal 2026 guidance, projecting Adjusted EBITDA of about $15 million, cash of about $48 million and net debt of about $37 million.
Q3 revenue was $9.0 million versus $8.4 million a year earlier; nine-month revenue was $16.3 million versus $43.3 million, reflecting the citrus wind-down.
Q3 net income attributable to common stockholders was $2.1 million ($0.29 per diluted share), compared with a loss of $18.3 million ($2.39 per share) in the prior-year quarter.
Fiscal 2026 guidance was raised to Adjusted EBITDA of about $15 million, with year-end cash of about $48 million and net debt of about $37 million.
The company repurchased about 245,000 shares for $10.0 million during the period.
Simon reported second-quarter 2026 results on August 10, 2026, with Real Estate FFO of $1.249 billion, or $3.29 per diluted share, up 7.9% from a year earlier. GAAP net income attributable to common stockholders fell to $483.1 million, or $1.49 per diluted share, from $556.1 million, or $1.70, a year earlier, and the prior-year figure included a $0.21 per share gain. The company raised its full-year 2026 Real Estate FFO per share guidance to $13.20 to $13.30 from $13.10 to $13.25.
Real Estate FFO was $1.249 billion, or $3.29 per diluted share, versus $1.154 billion, or $3.05, in the second quarter of 2025.
GAAP net income attributable to common stockholders was $483.1 million, or $1.49 per diluted share, versus $556.1 million, or $1.70, a year earlier.
Full-year 2026 Real Estate FFO per share guidance was raised to $13.20 to $13.30, from $13.10 to $13.25 previously.
Simon declared a third-quarter 2026 common dividend of $2.25 per share, up $0.10 or 4.7% year over year, payable September 30, 2026.
NIQ reported second-quarter 2026 revenue of $1,124.2 million, up 8.0% from a year earlier, and adjusted EBITDA of $261.9 million, up 21.9%. The company also raised its full-year 2026 guidance, but it still reported a net loss attributable to NIQ of $30.5 million, larger than the $2.7 million loss in the same quarter of 2025.
Revenue of $1,124.2 million, up 8.0% year over year; organic constant currency growth of 5.8%
Net loss attributable to NIQ of $30.5 million versus $2.7 million a year earlier; adjusted EPS of $0.27 versus a $(0.01) loss
Adjusted EBITDA of $261.9 million, up 21.9%; adjusted EBITDA margin of 23.3%, up 270 basis points
Full-year 2026 guidance raised to 5.2% to 5.6% organic constant currency revenue growth, 23.5% to 23.9% adjusted EBITDA margin and $245 million to $255 million of levered free cash flow
Tactile Medical reported second-quarter 2026 revenue up 9% year-over-year to $85.7 million and net income of $7.8 million, or $0.34 per diluted share, compared with $3.2 million, or $0.14 per diluted share, a year earlier. The company lowered the top end of its full-year 2026 revenue forecast to $360 million to $366 million from $360 million to $368 million, citing temporary inventory dynamics tied to the AffloVest launch, while keeping its adjusted EBITDA outlook of $49 million to $51 million unchanged. Shareholders get profit growth alongside a narrower sales outlook.
Q2 2026 total revenue was $85.7 million, up from $78.9 million; airway clearance sales fell 7% on temporary inventory dynamics at a few large DME providers.
Q2 2026 net income was $7.8 million, or $0.34 per diluted share, versus $3.2 million, or $0.14 per diluted share, in Q2 2025.
Full-year 2026 revenue guidance is now $360 million to $366 million, versus the prior $360 million to $368 million.
Adjusted EBITDA guidance of $49 million to $51 million was maintained; cash was $69.9 million as of June 30, 2026.
Public Policy Holding Company (PPHC) reported Q2 2026 revenue up 7.3% to $52.1 million, but Adjusted EBITDA fell 4.4% and adjusted EPS fell to $0.34 from $0.45. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, attributing the increase to acquisitions completed and announced in 2026, while stating its outlook for the underlying business is unchanged.
Q2 2026 revenue rose 7.3% to $52.1 million, with organic revenue growth of 3.9%; GAAP net loss narrowed to $3.7 million from $5.7 million.
Q2 Adjusted EBITDA fell 4.4% to $12.3 million, with margin of 23.5% versus 26.4% a year earlier; fully diluted adjusted EPS was $0.34 versus $0.45.
For H1 2026, revenue rose 16.3% to $102.3 million and Adjusted EBITDA rose 9.3% to $23.4 million.
Full-year 2026 revenue guidance raised to $213 million to $216 million from $205 million to $209 million; Adjusted EBITDA guidance raised to $48.5 million to $50.5 million from $46 million to $48 million.
Quanterix reported second-quarter 2026 revenue of $32.9 million, up 34% from $24.5 million a year earlier, but its net loss widened to $48.9 million, or $1.04 per share, including a $26.9 million goodwill impairment tied to the Akoya acquisition. The company cut its 2026 revenue outlook to $142-148 million from $169-174 million and lowered its expected year-end 2026 cash balance to about $80 million from $100 million.
Q2 2026 revenue was $32.9 million, up 34% from $24.5 million; net loss was $48.9 million, or $1.04 per share, versus $30.0 million, or $0.77 per share, in Q2 2025.
2026 revenue outlook was lowered to $142-148 million from $169-174 million, and non-GAAP gross margin guidance is now 48-50% versus 49-53% previously.
Cash flow breakeven is now expected in 2027, and year-end 2026 cash is forecast at about $80 million versus $100 million previously.
Jim Gute was named Chief Commercial Officer, announced alongside the results.
Heron Therapeutics reported second-quarter 2026 net revenue of $37.7 million, up 1.3% from a year earlier, while its net loss widened to $5.5 million from $2.4 million. The company withdrew its full-year 2026 net product sales and Adjusted EBITDA guidance after a June 2026 court decision on CINVANTI patents made the timing of potential generic entry hard to forecast, and it said it is considering strategic alternatives with no timetable set.
Q2 2026 net revenue was $37.7 million, up 1.3% from $37.2 million in Q2 2025; CINVANTI revenue fell 9.7% to $21.8 million.
Q2 2026 net loss was $5.5 million, or $0.03 per share, compared with a net loss of $2.4 million, or $0.02 per share, a year earlier.
Full-year 2026 guidance was withdrawn, citing the June 2026 U.S. District Court for the District of Delaware decision on CINVANTI patents.
Cash, cash equivalents and short-term investments totaled $42.7 million at June 30, 2026; the Hercules Capital credit facility was amended with a $13.5 million principal reduction at execution.
AirSculpt reported second-quarter 2026 revenue of $42.9 million, down 3% from a year earlier, and a wider net loss of $1.1 million. The company cut its full-year 2026 adjusted EBITDA outlook to approximately $12 million to $14 million while reaffirming revenue at the lower end of its $151 million to $157 million range, which weighs on shareholders' expectations for profit.
Q2 2026 revenue was $42.9 million, down from $44.0 million; net loss was $1.1 million versus $0.6 million a year earlier.
Adjusted EBITDA for Q2 2026 was $4.9 million versus $5.8 million; the full-year adjusted EBITDA outlook was reduced to approximately $12 million to $14 million.
Cash was $18.8 million and gross debt was approximately $44.2 million as of June 30, 2026.
On August 7, 2026, an amended term loan extended maturity to November 2027; a $2.5 million payment is due on or before September 30, 2026.
RadNet reported second-quarter 2026 revenue of $622.7 million, up 25.0%, and Adjusted EBITDA of $99.7 million, up 22.7%, both described as quarterly records. The company raised its 2026 Imaging Center guidance for revenue, Adjusted EBITDA and free cash flow, but GAAP net income attributable to RadNet fell to $7.5 million ($0.10 per diluted share) from $14.5 million ($0.19) a year earlier.
Total Company Revenue rose 25.0% to $622.7 million and Adjusted EBITDA rose 22.7% to $99.7 million versus Q2 2025.
Net income attributable to RadNet was $7.5 million, or $0.10 per diluted share, compared with $14.5 million, or $0.19, in Q2 2025.
Adjusted EPS was $0.29 versus $0.34 in Q2 2025, after one-time items including $6.6 million of acquisition transaction costs and a $3.4 million debt restructuring loss.
2026 Imaging Center guidance raised to revenue of $2,370-$2,420 million and Adjusted EBITDA of $345-$358 million; Digital Health guidance reaffirmed.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.